

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included. Medicines included are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise on their preferred medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine

Condition being treated

NHSGGC Decision

Date of decision

acalabrutinib	In combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).	Routinely available in line with local or regional guidance	08/06/2026
Calquence®			
SMC2893			
amivantamab	In combination with lazertinib for the first line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
Rybrevant®			
SMC2834			
ataluren	Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.	Not routinely available as not recommended for use in NHSScotland	08/06/2026
Translarna®			
SMC2827			
axicabtagene ciloleucel	Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	08/06/2026
Yescarta®			
SMC2695			
belantamab mafodotin	in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	08/06/2026
Blenrep			
SMC2727			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
brentuximab vedotin Adcetris® SMC2925	For adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma (HL) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).	Not routinely available as not recommended for use in NHSScotland	08/06/2026
budesonide Kinpeygo® SMC2814	Treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g*). *equivalent to ≥90 mg/mmol]	Routinely available in line with local or regional guidance	08/06/2026
cabozantinib SMC2754	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
capsaicin Qutenza® SMC2861	Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
ciclosporin Vevizye® SMC2873	Treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.	Routinely available in line with national guidance	08/06/2026
darolutamide Nubeqa® SMC2940	Treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.	Not routinely available as not recommended for use in NHSScotland	08/06/2026
delgocitinib Anzupgo® SMC2817	Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate.	Routinely available in line with national guidance	08/06/2026
dupilumab Dupixent® SMC2851	As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
durvalumab Imfinzi® SMC2818	0 Monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
enfortumab vedotin Padcev® SMC2842	0 In combination with pembrolizumab, for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
exagamglogene autotemcel Casgevy® SMC2852	0 Treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the β^S/β^S , β^S/β^+ or β^S/β^0 genotype, for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
gefapixant Lyfnua® SMC2926	0 Treatment of refractory or unexplained chronic cough in adults.	Not routinely available as not recommended for use in NHSScotland	08/06/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
isatuximab Sarclisa® SMC2804	In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
marstacimab Hympavzi® SMC2759	for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: •severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or •severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.	Routinely available in line with national guidance	08/06/2026
nemolizumab Nemluvio® SMC2833	Treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30 kg, who are candidates for systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
nemolizumab Nemluvio® SMC2832	Treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.	Not routinely available as not recommended for use in NHSScotland	08/06/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
nintedanib Ofev® SMC2941	0 treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs) in children and adolescents from 6 to 17 years old	Not routinely available as not recommended for use in NHSScotland	08/06/2026
niraparib , abiraterone Akeega® SMC2942	0 In combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.	Not routinely available as not recommended for use in NHSScotland	08/06/2026
nivolumab, ipilimumab NCMAG126	0 Neoadjuvant treatment of adults with mismatch repair deficient or microsatellite instability-high locally advanced colon cancer classified as T4 or borderline resectable	Routinely available in line with local or regional guidance	08/06/2026
odevixibat Bylvay® SMC2843	0 Treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.	Routinely available in line with national guidance	08/06/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
osimertinib Tagrisso® SMC2815	0 Treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.	Routinely available in line with local or regional guidance	08/06/2026
peginterferon alfa-2a Pegasys® SMC2937	0 Monotherapy in adults for the treatment of essential thrombocythaemia.	Not routinely available as not recommended for use in NHSScotland	08/06/2026
peginterferon alfa-2a Pegasys® SMC2936	0 Monotherapy in adults for the treatment of polycythaemia vera	Not routinely available as not recommended for use in NHSScotland	08/06/2026
pembrolizumab Keytruda® SMC2829	0 In combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.	Routinely available in line with local or regional guidance	08/06/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
ribociclib Kisqali® SMC2803	In combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
Semaglutide Wegovy SMC2497	An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • ≥ 30 kg/m ² (obesity), or • ≥ 27 kg/m ² to < 30 kg/m ² (overweight) in the presence of at least one weight-related comorbidity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	08/06/2026
semaglutide Wegovy® SMC2872	As an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m ²)	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
sotatercept Winrevair® SMC2923	In combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
sparsentan Filspari® SMC2847	Treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥ 1.0 g/day (or urine protein-to-creatinine ratio ≥ 0.75 g/g*). *equivalent to ≥ 85 mg/mmol	Routinely available in line with local or regional guidance	08/06/2026
tafasitamab Minjuvi® SMC2943	In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy.	Not routinely available as not recommended for use in NHSScotland	08/06/2026
talquetamab Talvey® SMC2863	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
tirzepatide Mounjaro® SMC2653	For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m ² (obesity) or ≥ 27 kg/m ² to < 30 kg/m ² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	08/06/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
vanzacaftor, tezacaftor, deuterivacaftor Alyftrek® SMC2800	Treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	08/06/2026
vorasidenib Voranigo® SMC2844	Treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and paediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention.	Routinely available in line with local or regional guidance	08/06/2026
zolbetuximab Vyloy® SMC2839	In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	08/06/2026